> If Eli Lily is the only producer, how is the gray market being supplied? This makes no sense...
It turns out enterprising chemists and pharmacists are capable of reverse engineering.
I don't think it's that hard to figure out how someone might do it -- imagine having to reverse engineer food you've received, given many samples. Imagine some of those samples might have "fallen off the back of a truck".
> That being said, I'm waiting for oral GLP1 agonists. Injections are a hassle and gray market ones even more so
This is really going to be the second leg of adoption and will catapult GLP1s even further IMO. Rybelsus has not really seen a ton of popularity compared to the injections. That said, Orforglipron is Eli Lilly's upcoming oral GLP1 and it looks to have really good results:
Yes, chemists don't need to reverse engineer that (although they can) because it will be in the patent. I'm not sure if the production process is though.
It turns out enterprising chemists and pharmacists are capable of reverse engineering.
I don't think it's that hard to figure out how someone might do it -- imagine having to reverse engineer food you've received, given many samples. Imagine some of those samples might have "fallen off the back of a truck".
> That being said, I'm waiting for oral GLP1 agonists. Injections are a hassle and gray market ones even more so
This is really going to be the second leg of adoption and will catapult GLP1s even further IMO. Rybelsus has not really seen a ton of popularity compared to the injections. That said, Orforglipron is Eli Lilly's upcoming oral GLP1 and it looks to have really good results:
https://glp1.guide/content/updates-from-maritide-orforglipro...